FibroGen (id:7618 FGEN)
0.395 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 6:59:28 AM)
Exchange closed, opens in 1 day 2 hours
About FibroGen
Market Capitalization 33.73M
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Headquarters (address) |
409 Illinois Street San Francisco 94158 CA United States |
| Phone | 415 978 1200 |
| Website | https://www.fibrogen.com |
| Employees | 486 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | FGEN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.180 - 2.93 |
| Market Capitalization | 33.73M |
| P/E trailing | -0.135 |
| P/E forward | -0.485 |
| Price/Sale | 0.194 |
| Price/Book | -0.207 |
| Beta | 0.726 |
| EPS | -1.23 |
| EPS United States (ID:6, base:3402) | 24.22 |